Minimal important differences and self-identifying treatment response in chronic inflammatory demyelinating polyneuropathy.
dc.contributor.author | Rajabally, Yusuf A | |
dc.contributor.author | Afzal, Saadia | |
dc.contributor.author | Ghasemi, Majid | |
dc.date.accessioned | 2024-08-28T12:25:22Z | |
dc.date.available | 2024-08-28T12:25:22Z | |
dc.date.issued | 2021-04-20 | |
dc.identifier.citation | Rajabally YA, Afzal S, Ghasemi M. Minimal important differences and self-identifying treatment response in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2021 Jul;64(1):37-42. doi: 10.1002/mus.27250. Epub 2021 Apr 20 | en_US |
dc.identifier.issn | 0148-639X | |
dc.identifier.eissn | 1097-4598 | |
dc.identifier.doi | 10.1002/mus.27250 | |
dc.identifier.pmid | 33835480 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14200/5533 | |
dc.description.abstract | Introduction/aim: The use of outcome measures is recommended for chronic inflammatory demyelinating polyneuropathy (CIDP). Implications of minimal important differences (MID) to ascertain responder status are unknown. The reliability of patient-reported treatment-response in relation to clinically relevant change is also unknown. Methods: We retrospectively studied 72 subjects with "definite" or "probable" CIDP evaluated at pre-specified time-intervals pre- and post-treatment. We derived MID and the minimum detectable change with 95% confidence intervals (MDC95 ) for four scales. Scale sensitivities were determined with applicable MID-defined cutoffs (aMIDc), to detect subjects with self-identifying treatment response through a single question. Results: The use of MID was not valid for the Medical Research Council Sum Score, as MDC95 > MID. The aMIDc for the Overall Neuropathy Limitation Score (ONLS) was 1 (sensitivity: 84.7%). The aMIDc for the centile Inflammatory Rasch-built Overall Disability Scale (cI-RODS) was 8 (sensitivity: 62.3%). The aMIDc for grip strength was 4 kg (sensitivity: 79.1%). MID-defined amelioration of any one scale among ONLS, cI-RODS, or grip strength, significantly improved sensitivity to detect treatment-responders compared with the ONLS alone (McNemar test: P = .008, odds ratio: 3.36 [95% confidence interval: 1.44-7.86]). Patient-reported improvement was highly reliable in relation to MID-defined amelioration on any one scale. Discussion: In subjects with CIDP, MID-defined amelioration of any one of three commonly used outcome measures offers optimum relevance and sensitivity to detect self-identifying treatment-responders. Patient reliability to single-question ascertainment of response is high in relation to MID-defined clinical relevance. These findings support use of multiple outcome measures in CIDP monitoring and justify enhanced patient involvement in the process. | en_US |
dc.language.iso | en | en_US |
dc.publisher | John Wiley & Sons | en_US |
dc.relation.url | http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-4598 | en_US |
dc.rights | © 2021 Wiley Periodicals LLC. | |
dc.subject | Neurology | en_US |
dc.title | Minimal important differences and self-identifying treatment response in chronic inflammatory demyelinating polyneuropathy. | en_US |
dc.type | Article | en_US |
dc.source.journaltitle | Muscle & Nerve | en_US |
dc.source.volume | 64 | |
dc.source.issue | 1 | |
dc.source.beginpage | 37 | |
dc.source.endpage | 42 | |
dc.source.country | United States | |
rioxxterms.version | NA | en_US |
dc.contributor.trustauthor | Rajabally, Yusuf A | |
dc.contributor.trustauthor | Afzal, Saadia | |
dc.contributor.department | Neurology | en_US |
dc.contributor.department | Neurophysiology | en_US |
dc.contributor.role | Medical and Dental | en_US |
oa.grant.openaccess | na | en_US |